GlassScriptPhysician profile
Rodney Earl Todd
NPI 1629085907
$7,820.90
in general payments reported to CMS, 2019-2025
43 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $1,108 · 2021: $843 · 2022: $984 · 2023: $916 · 2024: $1,575 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,627 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,626.97 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,798.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $780.70 | 2021-2025 | Vraylar, Linzess, Ubrelvy |
| Pfizer INC. | $677.36 | 2019-2025 | |
| Lilly USA, LLC | $460.90 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $378.01 | 2019-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $364.49 | 2019-2022 | |
| Novo Nordisk INC | $336.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $317.32 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $311.51 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $226.49 | 2022-2024 | |
| Horizon Therapeutics Plc | $191.97 | 2020-2022 | |
| Axsome Therapeutics, INC. | $191.52 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.37 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $166.59 | 2019-2025 | Rexulti |
| Exact Sciences Corporation | $148.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.